| Old Articles: <Older 2111-2120 Newer> |
|---|
 |
The Motley Fool
June 21, 2005
Stephen D. Simpson |
American Healthways Sneezes Investors took the stock down after earnings, but the company is still in good health.   |
The Motley Fool
June 21, 2005
Brian Gorman |
Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note. |
The Motley Fool
June 21, 2005
Brian Gorman |
Wyeth's Lower Dosage The company's planned sales-force cutback shows its resolve to increase efficiency. Investors, this pharmaceutical remains the one to watch. |
The Motley Fool
June 20, 2005
Stephen D. Simpson |
Ouch! Guidant Zaps Itself Problems with ICDs have led to a voluntary recall and could fuel a class action suit. While Guidant is doing the right thing now, investors, patients, and doctors may well ask whether more should have been done sooner. |
BusinessWeek
June 27, 2005
Arlene Weintraub |
Stem Cells To Go ViaCell's goal is to mass-produce stem cells from umbilical cord blood. |
The Motley Fool
June 17, 2005
Ellen Dowling |
Nu Skin's New Tool The company is betting that increased sales in China and Japan will lift sagging stock prices. So far, so good: Nu Skin recently reported first-quarter 2005 earnings per share growth of 25% and record revenue of $289.4 million, up around 10% from the same quarter in 2004. |
The Motley Fool
June 17, 2005
W.D. Crotty |
Biotech's Apple Dumpling Gang Chiron has made a number of financial and planning mistakes in the production of its flu vaccine. |
BusinessWeek
June 27, 2005
Amy Barrett |
Color-Blind Drug Research Is Myopic Researchers will sometimes have to use the blunt instrument of race to help match patients with the right drugs. |
The Motley Fool
June 16, 2005
Karl Thiel |
BiDil's Bid for a Narrow Label Although things appear to be going NitroMed's way, there is a dark horse spoiler looming in the shadows that should keep investors on their toes today. The company is seeking FDA approval for African-Americans only, but what if BiDil is given a broader label acceptance? |
The Motley Fool
June 16, 2005
Stephen D. Simpson |
Farewell, Sweet Vicuron Pfizer purchased promising biotech Vicuron Pharmaceuticals for $29.10 as share in cash. Vicuron shareholders get a nice payday -- nearly 84% premium to its close and a 21% premium to its all-time high. The deal makes sense for Pfizer despite the high sticker price. |
| <Older 2111-2120 Newer> Return to current articles. |
